TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

Highlights Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Equities

600329

CNE000001808

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 08/05/2026			5-day change	1st Jan Change
42.24 ^CNY	+0.50%		+4.04%	-7.41%

04-30	Singapore Shares Surge More Than 1% as DBS Books Record Total Income	MT
04-30	Tianjin Pharmaceuticals Da Ren Tang's Attributable Profit Jumps 13% in Q1; Shares Up 5%	MT

Highlights

04-30	Tianjin Pharmaceuticals Da Ren Tang's Attributable Profit Jumps 13% in Q1; Shares Up 5%	MT
04-29	Tianjin Pharmaceutical Da Ren Tang posts qtrly revenue of RMB1.52 billion	RE
04-29	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025	MT
03-31	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Down 4% in 2025	MT
03-30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Proposes Final Dividend for Fiscal Year 2025	CI
03-30	Tianjin Pharmaceutical Da Ren Tang 2025 net profit down 4.4%	RE
03-30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-06	Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%	MT
02-02	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Interim Dividend for the Financial Year Ended 31 December 2025, Payable on or About February 12, 2026	CI
11-25	Tianjin Pharmaceutical Plant Receives Drug Registration Certificate	CI
31/10/25	Tianjin Pharmaceutical Da Ren Tang Q3 Profit Up 54%, Revenue Down 38%	MT
30/10/25	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
30/10/25	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Proposes Interim Dividend for Fiscal Year 2025	CI
30/10/25	Tianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3	MT
14/08/25	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Soars in Q2	MT
14/08/25	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
14/07/25	Tianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1	MT
14/07/25	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2025	CI
14/07/25	Tianjin Pharmaceutical Da Ren Tang sees H1 net profit up 180-204% Y/Y	RE
30/06/25	Tianjin Pharmaceutical Da Ren Tang Completes Disposal of 12% Stake in Tianjin TSKF; Shares Up 2%	MT
27/06/25	Haleon China Co., Ltd., and Haleon CH SARL completed the acquisition of 12% stake in Sino-American Tianjin Smith Kline & French Laboratories Ltd. from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.	CI
18/06/25	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Dividend for the Financial Period Ended 31 December 2024, Payable on or About 4 July 2025	CI
30/04/25	Tianjin Pharmaceutical Da Ren Tang Attributable Profit Shrinks in Q1	MT
29/04/25	Tianjin Pharma's Attributable Profit Slips 3% in Q1	MT